HIV protease inhibitors in gut barrier dysfunction and liver injury.

Abstract

The development of HIV protease inhibitors (HIV PIs) has been one of the most significant advances of the past two decades in controlling HIV infection. HIV PIs have been used successfully in highly active anti-retroviral therapy (HAART) for HIV infection, which is currently the most effective treatment available. Incorporation of HIV PIs in HAART causes profound and sustained suppression of viral replication, significantly reduces the morbidity and mortality of HIV infection, and prolongs the lifespan of HIV patients. However, in the era of HAART, drug-induced gastrointestinal (GI) side effects and hepatotoxicity have emerged as important potential complications of HIV therapy, particularly those regimens containing HIV PIs. In this mini-review, we highlight the current understanding of the mechanisms of HIV PI-associated GI and liver injury.

• Authors: Xudong Wu, Yunzhou Li, Kesong Peng, Huiping Zhou
• Journal: Current opinion in pharmacology (Curr Opin Pharmacol) Vol. 19 Pg. 61-6 (Dec 2014) ISSN: 1471-4973 [Electronic] England
• PMID: 25105480 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
• Copyright: Published by Elsevier Ltd.

Chemical References

• HIV Protease Inhibitors

Topics

• Animals
• Antiretroviral Therapy, Highly Active (adverse effects)
• Chemical and Drug Induced Liver Injury (etiology)
• Endoplasmic Reticulum Stress (drug effects)
• Gastrointestinal Diseases (chemically induced)
• Gastrointestinal Tract (drug effects)
• HIV Protease Inhibitors (adverse effects)
• Humans